@article{article, title  = {{DASL-HiCaP: A randomized, phase 3, double-blind trial of darolutamide with androgen-deprivation therapy and definitive or salvage radiation for localized very high-risk prostate cancer.}},

 publisher = {{American Society of Clinical Oncology (ASCO)}},

 url = {{http://dx.doi.org/10.1200/jco.2023.41.6_suppl.tps396 }},

 year = {{2023}},

 month = {{2}},

 author = {{Niazi T and McBride SM and Williams S and Davis ID and Stockler MR and Martin AJ and Chung HT and Roncolato F and Ebacher A and Khoo E and Martin J et al}},

 doi = {{10.1200/jco.2023.41.6_suppl.tps396}},

 volume = {{41}},

 journal = {{Journal of Clinical Oncology}},

 issue = {{6_suppl}},

 pages = {{TPS396-TPS396}},

 note = {{Accessed on 2024/12/21}}}